Health Affairs March 24, 2023
Troyen A. Brennan

The high price of medications is driving many different policy initiatives aimed at providing relief for patients and health care payers. The Inflation Reduction Act is the most comprehensive example, as the federal government commences negotiation of prices with manufacturers for a limited number of medications. Other proposals are more focused, such as the cap on out-of-pocket spending for patients with diabetes in the Medicare Part D program who must purchase insulin. In the same vein, the state of California has recently sued insulin producers and pharmacy benefit managers, alleging unsound business practices and seeking relief for patients unable to afford insulin. Many other beneficiaries and payers are now getting relief from high prices through the so-called 340B program, which...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
New 'how-to guide' for future rapid vaccine development
Infographic: R&D Spending Growth of Top Pharma Companies
Medicare prescription drug pricing variance: 5 things to know
Payer group 'deeply concerned' by Medicare weight loss drug coverage proposal
Adoption Of Model-Informed Drug Development Can Improve Pharma ROI

Share This Article